Gene Delivery Systems Market

Gene Delivery Systems Market Outlook (2022-2027)

The global gene delivery systems market currently accounts for a valuation of US$ 3 billion and is expected to reach US$ 4.1 billion by the end of 2027. Global demand for gene delivery systems is predicted to magnify at a CAGR of 6.5% from 2022 to 2027.

Demand for viral gene delivery systems is anticipated to rise rapidly at a CAGR of 7% through 2027. Viral gene delivery systems are used for treating genetic illnesses caused by the insertion or deletion of a gene.

Report Attributes	Details
Gene Delivery Systems Market Size (2022)	US$ 3 Billion
Projected Market Value (2027)	US$ 4.1 Billion
Global Market Growth Rate (2022-2027)	6.5% CAGR
Market Share of Viral Gene Delivery	85%
Share in Gene Therapy Market (2022)	30%
Key Companies Profiled	Amgen, Inc. Bayer AG Pfizer, Inc. Novartis AG Johnson & Johnson Human Stem Cells Institute Oxford Biomedica plc Shanghai Sunway Biotech Co., Ltd. Sibiono GeneTech Co. Ltd.

Demand Analysis of Gene Delivery Systems (2017-2021) Vs Market Projections (2022-2027)

“Rising Prevalence of Chronic Diseases Driving Demand for Gene Delivery Systems”

According to Fact.MR, a market research and competitive intelligence provider, the gene delivery systems market is projected to increase at a CAGR of 6.5% from 2022 to 2027.

Gene delivery systems can significantly improve the human therapies used to cure disease. A process called gene delivery inserts foreign DNA into host cells. Growing adoption of targeted therapies and innovations in gene delivery systems are expected to drive market expansion over the coming years.

Market growth is primarily driven by the rising prevalence of chronic diseases and the growing demand for targeted medicines. Market expansion has been fueled by the expanding ongoing research and development in the field of genetics at a global level, increasing need for genetic disorder therapeutics, and rising demand for self-administration tools for home-based health care.

Other factors that are anticipated to contribute to market expansion include the rising demand for targeted and low-dose frequency drug delivery, the increasing need for advanced technologies for targeted systems, and the introduction of new and superior methods such as adenovirus vectors, lentivirus vectors, and retrovirus vectors.

All of these important variables are anticipated to fuel market expansion for gene delivery systems over the coming years.

What Aspects Drive Gene Delivery Systems Market Growth?

“Development of Cell & Gene Therapies Supporting Market Expansion”

The development of cell and gene therapies has significantly altered not just how genetic and incurable diseases are treated, but also how the entire pharmaceutical industry is structured. One of the main factors influencing the market for gene delivery methods is the rapidly changing landscape of innovative medicines.

The global market for gene delivery systems is expanding due to the increased prevalence of different chronic diseases such as cancer, diabetes, cardiovascular diseases, and other chronic diseases as well as technological advancements in drug administration.

The demand for gene delivery solutions has increased as a result of patients' and physicians' changing preferences. The development of the global market for gene delivery systems has been considerably aided by the advent of auto-injectors, genealogy products & services, biopharmaceutical classification techniques, implants with configurable shapes and sizes, and adaptive aerosol delivery systems.

The demand for gene delivery systems has increased due to the increasing use of gene treatments and novel drugs as a result of growing public awareness about the existence of new medications that can successfully treat chronic conditions. One of the key factors propelling the market is the increase in funding for the discovery of new pharmaceuticals and therapies for the treatment of incurable diseases.

“Introduction of Several Revolutionary Tools for Genetic Modifications”

The activation of physical gene delivery techniques such as megnetoporation, optoporation, sonoporation, and electroporation has been made possible by emerging nanotechnology and physical technology. More people are paying attention to this technological breakthrough because of its better functionality and nontoxicity. These factors have also increased the use of gene delivery systems.

Some of the main driving factors are technological advancements in viral vectors, an expanding pipeline of advanced therapies, and an increase in the number of regulatory approvals for innovative therapy products.

The development of new gene delivery techniques has been aided by the introduction of several revolutionary tools for genetic modifications that have made it easier for the scientific community to outline the complexities of disease at the genomic level.

The market revenue is also being boosted by continuous research to create clinically useful vectors, including adeno-associated virus vectors, sendai virus vectors, and herpes simplex virus vectors to treat chronic diseases such as cancer, Alzheimer's, and others with innovative medicines.

How is Market Expansion Being Restrained to Some Extent?

“High Treatment Costs and Efficacy & Safety Concerns”

The market is anticipated to be constrained by high treatment costs, efficacy and safety concerns, long clinical study procedures, stringent regulations for product approvals, and an increase in drug recalls.

How are Start-ups Sculpting Their Progress in the Gene Delivery Systems Market?

“Aspiring Market Players Focused on Innovations in Non-viral Gene Therapies”

It is projected that the growing public and private interest in gene delivery technologies would hasten the entry of new firms into the market. New companies are investing in R&D to create high-end gene delivery systems and address problems, worries, and adverse effects associated with their use.

Viral vectors are limited by the size of the virus chassis, which makes it difficult to transmit significant genetic payloads. Additionally, some people may develop cancer or experience inflammatory reactions as a result of viral gene therapy. These issues are resolved by non-viral gene therapies, which successfully expand the patient population who can benefit from gene therapy.

• Generation Bio, a start-up based in the U.S., provides non-viral gene treatment options. Their technology, which uses a unique closed-ended deoxyribonucleic acid (ceDNA) system, may deliver one or multiple genes to a cell. It also can provide long-lasting gene expression by allowing higher loads.

Which Region Spearheads Gene Delivery System Demand?

“Higher Consumer Awareness of Improved Drug Delivery Systems North America”

North America leads the gene delivery systems market. The market is expanding as a result of rising demand for biological gene delivery systems, rising adoption of innovative products, and rising consumer awareness of improved drug delivery systems.

Increased prevalence of chronic diseases, technological advancements in genetic analyzer systems, and the presence of key players are driving market growth in the region.

Increasing rates of hospitalizations, technological advancements in drug delivery systems, and rising research and innovation initiatives for the development of gene delivery systems are driving market expansion in the region.

Country-wise Insights

Why is the Market for Gene Delivery Systems Prominent in the U.S?

“Growing Public & Private Investments in Development of Advanced Gene Therapy Products”

According to research, approximately 60% of the U.S. population has at least one chronic illness. The U.S. market is growing as a result of rising viral gene delivery system usage, growing public and private investments in the development of advanced gene therapy products, and a well-established biotechnology industry.

The growing awareness among the population of advanced technology for the treatment of hereditary and rising involvement by key businesses in the production and marketing of gene delivery technologies are the factors driving market expansion.

Why are Suppliers of Gene Delivery Systems Attracted to China?

“Rapid Expansion of Pharmaceutical Industry in China”

The gene delivery systems market in China is expected to rise at a CAGR of 6% over the forecast period.

China is recognised as a gene therapy hub. Market expansion is attributed to the growing acceptance of personalized medications, the rapid expansion of the pharmaceutical industry, the presence of a large population, and the rising incidence of diseases brought on by pollution as a result of rapid industrialization and urbanization.

Due to a huge patient base and the increase of production capacity by major players to meet the rising demand for gene delivery systems, the market in China is anticipated to grow quickly.

Category-wise Insights

Why are Viral Gene Delivery Systems Mostly Preferred?

“Strong Emphasis by Governments on Public Education about Viral Gene Delivery Systems”

Based on the delivery, the gene delivery systems market is divided into viral gene delivery and non-viral gene delivery. Viral gene delivery systems account for 85% share of the global market.

Due to characteristics such as long-term expression, short-term expression, and therapeutic gene efficacy as well as recent technological advancements that have created numerous growth opportunities in the healthcare sector, it is anticipated that viral gene delivery systems will continue to hold a dominant market share. Market growth of gene delivery systems has also been aided by the rising prevalence of cardiovascular ailments.

These gene delivery technologies have gained widespread acceptance as a result of governments placing a greater emphasis on public education regarding these treatments.

Which Application Accounts for the Highest Sales of Gene Delivery Systems?

“Growing Prevalence of Cancer Driving High Demand for Gene Delivery Systems in Oncology”

The gene delivery systems market is segmented into infectious diseases, oncology, CVD, urology, CNS, and others based on the application. The global gene delivery systems market is dominated by the oncology segment in terms of revenue. Global demand for gene delivery devices is being driven by an increase in cancer incidence in all regions.

The demand for innovative drug delivery systems in the oncology segment has increased due to the rising incidence of malignancies such as leukemia, brain tumors, colon cancer, stomach cancer, and others.

Growing prevalence of cancer disorders, the increased emphasis on research to create a successful cancer treatment, and rising funding in cancer research are the key drivers of segment growth.

Competitive Landscape

Market expansion is being fueled by strategic agreements formed by companies developing cell and gene therapies with vector suppliers. Due to the presence of numerous domestic and international producers of gene delivery systems, the global market for gene delivery systems is very competitive.

For instance :

• Nanoparticles demonstrated their effectiveness as prospective carriers for clinical utilization due to their customizable shape and biological activities.
• Brammer Bio, a company that produces viral vectors for gene therapies, was acquired by Thermo Fisher Scientific.

Segments of Gene Delivery Systems Industry Research

• By Delivery :

  • Viral Gene Delivery
  • Non-viral Gene Delivery

• By Route of Administration :

  • Oral
  • Injectable
  • Inhalation
  • Transdermal
  • Ocular
  • Nasal
  • Others

• By Application :

  • Infectious Diseases
  • Oncology
  • CVD
  • Urology
  • CNS
  • Others

• By Region :

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa